Ozempic 1 mg solution for injection in pre-filled pen clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?
This study looks at whether a medicine called semaglutide (often known as Ozempic) can help people with schizophrenia on certain antipsychotic medicines. Researchers want to see if it can prevent or slow down problems with blood sugar, like pre-diabetes or diabetes, in these patients.
For: SchizophreniaDenmark - Ongoing, recruitingTherapeutic use (Phase IV)
Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension
This study looks at whether certain weight-loss medications (Wegovy, Ozempic) can help people with a condition called Idiopathic Intracranial Hypertension (IIH). Researchers want to see if losing weight quickly with these medicines can improve brain pressure and other symptoms over 8 weeks and then 10 months.
For: Idiopathic Intracranial HypertensionDenmark - AuthorisedTherapeutic exploratory (Phase II)
An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.
This study is looking at whether a weekly injection called semaglutide, combined with counselling, can help people reduce their cravings and use of certain drugs, often called 'chemsex' drugs. It's a first step to see if this treatment could be helpful.
For: Craving for and use of chemsex-related drugsBelgium - AuthorisedTherapeutic use (Phase IV)
Healing Diabetic Foot Ulcers with Semaglutide
This study is looking at how well a medicine called semaglutide (also known as Ozempic) helps diabetic foot ulcers to heal. It compares how quickly ulcers close when people use semaglutide alongside their usual care, against those who only receive standard care.
For: Diabetic foot ulcerNetherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.
For: Mild cognitive impairment (MCI) or mild dementia · both of the Alzheimer’s typeDenmark · Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight
For: Participants with T2D and overweightCzechia · Portugal · Spain